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Vasodilator drugs produce tachycardia and an increase
in circulating plasma norepinephrine in normal subjects.
In contrast, heart rate does not change when the same
drugs are given to patients with congestive heart failure.
To assess if this difference could be related to a different
reflex activation of the sympathetic nervous system, the
response of plasma norepinephrine to nitroprusside in-
fusion and to head-up tilt was studied in 5 normal sub-
jects and in 46 patients with chronic congestive heart
failure. Norepinephrine and heart rate increased signif·
icantly during both stimuli in normal subjects but were
unchanged during nitroprusside infusion for the entire
group of patients with heart failure , with considerable
variability in individual responses. In 2~ patients (Group
I) norepinephrine increased during nitroprusside infu-
sion, while in the remaining 25 (Group II) noreplneph-
Patients with congestive heart failure have an attenuated
cardiac reflex response to changes in body position (1,2)
and administration of vasodilator drugs (3-5) . The mech-
anism accounting for this diminished response has not been
clarified and its clinical significance is not understood.
In the present study we explored the response to infusion
of sodium nitroprusside and orthostasis in patients with
congestive heart failure and compared it with the response
in normal volunteers. The results suggest that complete in-
hibition of the normal increaseof plasma norepinephrine in
response to these stresses in a subset of patients with heart
failure is indicative of an abnormality of baroreceptor and
mechanoreceptor function that may be a marker for a poor
prognosis.
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rine decreased. The hemodynamic response to nitro-
prusside was similar in the two groups, thus suggesting
that the different changes in plasma norepinephrine could
not be explained on the basis of a different hemodynamic
response to the drug. Plasma norepinephrine also did
not change significantly in Group II during tilt, although
the decrease in intracardiac pressure and the increase
in peripheral resistance were similar to those in Group
I who increased norepinephrine normally by 56%.
These data indicate that a subset of patients with
severe ventricular dysfunction have an abnormal hu-
moral, reflex sympathetic response to changes in arterial
or intracardiac pressure, or both. The higher mortality
in Group II suggests that this alteration in the sympa-
thetic response may be a marker of the severity and
prognosis of heart failure.
Methods
Study patients. Forty-six patients (38 men and 8 women,
mean age [±standard deviation] 56.4 ± 15 years) with
chronic congestive heart failure refractory to optimal con-
ventional therapy with digitalis and diuretic agents were
evaluated. The diagnosis of congestive heart failure was
established clinically by a history of fatigue or dyspnea, or
both, the presence of a third heart sound, pulmonary rales,
jugular venous distension or peripheral edema and radio-
graphic evidence of an enlarged heart and pulmonary vas-
cular congestion. Twenty-seven subjects were in New York
Heart Association (6) functional class III and 19 were con-
sidered to be in class IV, All patients had normal sinus
rhythm.
Heartfailure was due to ischemic cardiomyopathy in 3J
patients and primary cardiomyopathy in J5 patients. The
former diagnosis was based on a history of documented
myocardial infarction or angiographically demonstrated
coronary artery disease. The diagnosis of primary cardio-
myopathy was made when no other cause of heart failure
could be demonstrated. Patients with acute myocardial in·
farction within the previous 3 months, angina pectoris, ar-
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terial hypertension, primary valvular heart disease or pri-
mary pulmonary disease were excluded. The study of patients
with congestive heart failure was initiated on July 7, 1976,
the recruitment period was terminated on December 31,
1980 and the follow-up period was extended up to June 30,
1982.
No patients received vasodilator drugs for at least 72
hours before the study. Most patients were receiving daily
maintenance doses of digoxin. Diuretic drugs were discon-
tinued 72 hours before the study in 28 patients but were
omitted only on the day of study in the other 18 patients.
A previous study from this laboratory (7) showed that plasma
norepinephrine and plasma renin activity were similar in
patients with congestive heart failure who were or were not
taking a diuretic drug.
Studies also were carried out in five normal male vol-
unteers (mean age 23 ± 3 years). The study was approved
by the Committee on the Use of Human Subjects in Research
of the University of Minnesota (February 24,1976). Written
informed consent was obtained from each subject.
Procedures. In patients with congestive heart failure a
7F thermodilution Swan-Ganz flow-directed balloon-tipped
catheter was inserted percutaneously under local anesthesia
with 1% xylocaine by way of an antecubital or femoral vein
and advanced into the pulmonary artery for measurement
of right atrial and pulmonary artery and capillary wedge
pressures. Systemic arterial pressure was measured directly
with a short Teflon needle inserted into the brachial artery.
Pressures were measured using Statham P23Db pressure
transducers connected to a Hewlett-Packard multichannel
recorder. The midaxillary line was used as a zero reference
level. Mean pressures were obtained by electronic damping.
Left ventricular filling pressure was recorded as pulmonary
wedge or diastolic pressure, the same variable being used
during the study in each individual patient. Cardiac output
was measured in triplicate with the thermodilution technique
(8) injecting 10 ml of iced (0 to 5°C) 5% dextrose in water
with a model 3700 thermodilution injector (OMP Labora-
tories). Cardiac output was calculated with an Edwards Lab-
oratories 9510 A cardiac output computer. Heart rate was
monitored continuously during the study from the elec-
trocardiogram.
Systemic vascular resistance (SVR) in dynes-s-cm -5 was
calculated from the following formula: SVR ::::: 80 x (MAP
- mrap)/CO, where MAP is mean systemic arterial pressure
in mm Hg, mrap is mean right atrial pressure in mm Hg
and CO is cardiac output in liters/min.
Central venous blood samples were obtainedfor the mea-
surement of plasma norepinephrine levels by radioenzy-
matic assay (9) using a commercially available Cat-A-Kit
(Upjohn Company). Duplicate measurements by this method
have a coefficient of variation of 8.4% for norepinephrine
in our laboratory (7).
In normal subjects. systemic arterial pressure was mea-
sured by cuff and heart rate was monitored through an
electrocardiographic lead. Cardiac output was determined
by the carbon dioxide rebreathing method (10). Blood sam-
ples for the measurement of plasma norepinephrine were
obtained through a peripheral venous cannula. The same
cannula was used for the infusion of nitroprusside.
Protocol. Baseline measurements were obtained after a
minimum of at least 30 minutes of supine rest after posi-
tioning the catheters. Nitroprusside (Nipride, Hoffmann-La
Roche, Inc.) was then infused into a peripheral vein by an
IVAC infusion pump starting at a dose of 10 p.g/min, with
increases of 10 p.g/min every 5 minutes until either pul-
monary wedge pressure decreased to 40% below the control
value or systolic arterial pressure decreased to less than 90
mm Hg. The average dose required to achieve this hemo-
dynamic end point was 82 ± 8 p.g/min in patients with
congestive heart failure and 174 ± 26 p.g/min in normal
subjects. All measurements made in the baseline period were
repeated after 15 minutes of stable infusion of the peak dose
of nitroprusside.
In normal subjects and in 15 patients with congestive
heart failure. the response to 60° upright tilt was assessed
before infusion of nitroprusside. Hemodynamic measure-
ments and plasma catecholamines were determined after 10
minutes of head-up tilt. Prenitroprusside control measure-
ments were repeated 30 minutes after patients had been
returned to the supine position.
Statistical analysis. Statistical analysis of the difference
between normal subjects and patients with congestive heart
failure and between the two patient groups with congestive
heart failure was performed through the analysis of variance.
The paired t test was used for statistical analysis of data
after interventions. Chi-square testing was used to analyze
the data on mortality, and life table analysis was performed
utilizing the Gehan's Wilcoxon test (11). Data are presented
as mean ± standard error of the mean.
Results
Normal subjects. The baseline hemodynamic data in
five normal subjects are compared with those during 60°
head-up tilt and at peak effect of nitroprusside infusion in
Table 1. Head-up tilt caused no change in mean arterial
pressure, the decrease in cardiac output being counterbal-
anced by an increase in systemic vascular resistance. The
infusion of sodium nitroprusside produced a statistically
significant decrease (p < 0.01) in arterial pressure and in
systemic vascular resistance. Reflex activation of the sym-
pathetic nervous system was noted in response to both in-
terventions with a significant increase in plasma norepi-
nephrine levels.
Patients with congestive heart failure. Plasma nor-
epinephrine in the control period (Fig. 1) was significantly
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Table 1. Hemodynamic Response to 60° Head-Up Tilt and to Nitroprusside Infusion in Normal Subjects
HR MAP CI SI SVR PNE
(beats/min) (mm Hg) (hters/mm per m') (rnl/rrr') (dynes-s-cm - ') (pg/ml)
Control 58.0 ± 1.8 88.0 ± 1.1 3.45 ± 0.33 58.5 ± 3.8 974 ± 51 220 ± 38
Ttlt 66.4 ± 5.8 890 ± 20 3 14 ± 031 482 ± 4.9 1199 ± 115 346 ± 46*
Recontrol 58.6 ± 2.0 87.4 ± 0.6 361±0.12 62.5 ± 3.4 982 ± 47 218 ± 34
NP 78.4 ± 2.1* 72.4 ± I 3* 375 ± 033 477 ± 37* 810 ± 77* 432 ± 63*
*Differences between control and tilt. recontrol and nitroprusside infusion (NP) significantat a probability (p) level of < 001.
Mean values ± standard error of the mean are shown. CI = cardiac index, HR = heart rate; MAP = mean artenal pressure; PNE = plasma
norepinephrine; SI = stroke index, SVR = systemic vascular resistance
•
Figure 1. Response of plasma norepinephrine (PNE) and heart
rate (HR) to nitroprusside infusion (NP) in 5 normal subjects (tri-
angles) and 46 patients with congestive heart failure (CHF) (cir-
cles). Symbols above the control columns (C) indicate a significant
difference between normal subjects and patients with congestive
heart failure; symbols in NP columns indicate significant changes
from control during nitroprusside infusion. *p (probability) < 0.01,
tp < 0.05. Mean values ± standard error of the mean are shown.
PNE HR
pg/ml b/min
800 • Norma's 100
• CHF
patients (Group II) norepinephrine did not change or even
decrease during infusion of nitroprusside, These two groups
were of the same age and received a similar dose of nitro-
prusside (Table 2). Furthermore, there was no difference in
the pre-study drug regimen (diuretic drugs and vasodilators)
between the two groups.
Hemodynamic changes in Group I versus Group II.
Figure 2 shows the hemodynamic changes during infusion
of nitroprusside in these two subgroups of patients, Plasma
norepinephrine level was significantly higher in the control
period in Group II patients than in Group I (751 ± 77 pg/
ml versus 442 ± 41, probability [p] < 0,01). Group II
patients also had a slightly faster heart rate (p < 0.05) and
higher mean pulmonary arterial (38,6 ± 1.8 mm Hg versus
32.7 ± 1.7, p < 0.05) and capillary wedge pressures (25,0
± 1.2 mm Hg versus 21.4 ± 1.5, p < 0.05), Cardiac
index and mean arterial pressure were similar in the two
groups.
The hemodynamic response to nitroprusside was similar
in both groups. Mean arterial pressure decreased from 81.2
± 2.3 to 70.8 ± 1.9 mm Hg (p < 0.01) in Group I and
from 82.5 ± 2.2 to 72.7 ± 3,8 mm Hg (p < 0.01) in
Group II; mean pulmonary pressure decreased from 32.7
± 1.7 to 23.9 ± 1.9 mm Hg (p < 0.01) in Group 1 and
from 38.6 ± 1.8 to 27.9 ± 1.9 mm Hg (p < 0.01) in
Group II; mean pulmonary wedge pressure decreased from
21.4 ± 1.5 to 14.5 ± 1.8 mm Hg (p < 0.01) in Group I
and from 25.0 ± 1.2 to 15.7 ± 1.4 mm Hg (p < 0.01)
in Group II. The increase in cardiac index was significant
(p < 0.01) and similar in the two groups. Heart rate was
unchanged in Group I but decreased slightly in Group II;
the difference was not statistically significant.
Because Group I patients had a slightly lower baseline
cardiac filling pressure than Group II patients, a decrease to
low levels during nitroprusside infusion could account for
the sympathetic stimulation in this group. Therefore, data
were reexamined excluding patients whose pulmonary wedge
pressure was reduced to less than 15 mm Hg by nitroprus-
side. This subset (five subjects) of Group I whose pulmonary
wedge pressure remained above 15 mm Hg still exhibited
an increase in plasma norepinephrine in response to nitro-
prusside (501 ± 21 to 634 ± 56 pg/ml). The same analysis
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higher in patients with congestive heart failure than in the
normal subjects. Heart rate also was significantly faster in
the patients with heart failure. In contrast to the increase in
heart rate and plasma norepinephrine levels during nitro-
prusside infusion in normal subjects, patients with heart
failure exhibited neither an increase in plasma norepineph-
rine (from 599 ± 69 to 603 ± 40 pg/ml, not significant)
nor an increase in heart rate during nitroprusside infusion
(from 80.4 ± 2 to 79.5 ± 1.7 beats/min). Although plasma
norepinephrine did not change during nitroprusside infusion
for the entire group of patients with congestive failure, there
was considerable variability in the individual response.
Congestive heart failure subgroups. To explore the
mechanisms involved in the different responses to nitro-
prusside we arbitrarily separated the group of 46 patients
into those who did and did not exhibit an increase in plasma
norepinephrine during the infusion. Because duplicate mea-
surements for norepinephrine have a coefficient of variation
of 8.4% in our laboratory, patients whose plasma norepi-
nephrine increased more than 16.8% composed Group I.
Twenty-one patients met these criteria. In the remaining 25
600
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Table 2. Characteristics of Patients Whose Plasma Norepinephrine Increased (Group I) and Did Not Increase (Group II) During
Nitroprusside Infusion
NYHA Nitroprusside
Plasma Norepinephrine
Functional Dose
(pg/ml)
Group n Age (yr) Diagnosis Class (ltg/min) Control NItroprusside
21 56,0 ± 3 I = 15; III = 13; 84,2 ± 11.6 442 ± 41 636 ± 62
P = 6 IV = 8
11 25 55,5 ± 3 1= 16; III = 14; 78,1 ± 10,8 751 ± 77 591 ± 56
P = 9 IV = II
Mean values ± standard error of the mean values of nitroprusside dose and plasma norepmephnne are given.
I = ischemic cardiomyopathy; P = primary cardiomyopathy; n = number of subjects; NYHA = New York Heart Association.
of the data was performed for Group II, in which 10 subjects
had a pulmonary wedge pressure that remained above 15
mm Hg. In this subset, plasma norepinephrine decreased
during nitroprusside infusion, from 930 ± 96 to 718 ± 75
pg/ml.
Response to head-up tilt. The hormonal changes after
10 minutes of 60° head-up tilt are depicted in Table 3. Five
normal subjects and eight patients in Group I and seven in
Group II were studied. Plasma norepinephrine levels at rest
were higher in the subjects with congestive heart failure
than in the normal subjects and more elevated in Group II
than in Group I. In response to upright tilt, plasma norepi-
nephrine increased significantly (p < 0,01) in normal sub-
jects and Group I patients by 126 pg/ml (57%) and 215 pg/
ml (56%), respectively. In Group II, plasma norepinephrine
did not change significantly despite the fact that head-up tilt
produced similar hemodynamic changes in the two groups
of patients (Fig, 3), During tilt, no change in heart rate or
arterial pressure occurred in either subgroup of patients; in
both groups cardiac index decreased, systemic vascular re-
sistance increased and there was a sharp decline in the right
atrial and mean pulmonary wedge pressures.
Follow-up. Follow-up of the patients with congestive
heart failure showed that patients in Group II had a signif-
icantly higher mortality than patients in Group I. On June
30, 1982, official termination of the follow-up study, only
1 (4%) of 25 patients in Group II was still alive, whereas
8 (38%) of 21 patients in Group I were alive; this difference
(chi-square test) was highly significant (p < 0.01). The
follow-up period averaged 12.7 months in patients in Group
II (range 15 days to 51 months) and 21.8 months in Group
I patients (range 2 days to 60 months). The probability of
survival for the two groups is shown in Figure 4. The overall
difference between the two groups, as measured by Gehan's
Wilcoxon test, did not reach statistical significance (p <
0.076). This was due to the almost identical mortality rate
PNE HR CI
pg/ml b/min Llmin/M 2
1000 100 2.8• ~.800 r~: t600 i- -i 2.4 /""1· Figure 2. Hemodynamic and humoral response to75 2------"'1 nitroprusside (NP) infusion in Group I (open squares)
400
Q-' ..... " and in Group II (filled squares) patients with
!{/200 2,0 congestive heart failure, Mean values ± standarderror of the mean are shown for cardiac index (CI);
0 50 Or I I heart rate (HR); mean arterial pressure (MAP); mean
C NP C NP C NP capillary wedge pressure (mcwp); mean pulmonary
MAP MPP mcwp
pressure (MPP) and plasma norepinephrine (PNE)
mmHg mmHg mmHg
in the control state (C) and at peak nitroprusside
100 50 infusion, Symbols above the C columns indicate a
t 30 t significant difference in control values between the
i • two groups; symbols in the NP columns indicate§i~ Q-~i 20 ~~ significant changes from control during nitroprus-.... . side infusion. *p < 0,01, tp < 0,05.
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Table 3. Response of Plasma Norepinephrine to 60°
Head-Up Tilt
Plasma Norepinephrine
(pg/ml)
Group n Control 60° Head-Up Tilt
Normal 5 220 ± 38 346 ± 46*
CHF Group I 8 378 ± 56 593 ± 70*
CHF Group II 7 683 ± 109 757 ± 122
*Differences from control significant at p < 0.01. CHF = conges-
tive heart failure; n = number of subjects; mean values ± standard error
of the mean are presented.
during the first 9 months of follow-up; thereafter, the dif-
ference is clearly evident. No standard treatment regimen
was employed during this observation period. However, all
patients in both groups were being treated with digitalis,
diuretic drugs and some form of vasodilator therapy.
Discussion
The adrenergic nervous system is activated in normal
subjects in response to peripheralvasodilation, which produces
a decrease in arterial and atrial pressures, and to orthostasis,
which decreases venous return. Upright tilt and nitroprus-
side infusion promoted in our normal subjects a reflex sym-
pathetic stimulation as reflected by a significant increase in
plasma norepinephrine and heart rate. Combined venous and
arterialvasodilationproduced by nitroprusside (12-14) seemed
to be a more powerful stimulus for the reflexive release of
catecholamines (+ 96%) than the reduction in venous return
during head-up tilting (+ 57%). This observation is con-
sistent with the likelihood that nitroprusside infusion results
in stimulation of both low pressure mechanoreceptors and
high pressure baroreceptors whereas tilt predominantly stim-
ulates the low pressure receptors (15).
The sympathetic nervous system in congestive heart
failure. Dysfunction of the sympathetic nervous system in
patients with chronic congestive heart failure has been de-
scribed extensively. Whereas sympathetic activity appar-
ently is enhanced at rest and during exercise, and plasma
catecholamines are significantly augmented in patients with
heart failure (7,16-19), the chronotropic responses to phys-
iologic stimuli are impaired. In fact, heart rate usually shows
little change in patients with congestive heart failure in
response to the decrease in arterial pressure during vaso-
dilator therapy (3-5) and orthostasis (I, 2). This attenuated
chronotropic response, confirmed in the present studies,
could result from several possible mechanisms: I) reduced
hemodynamic stress produced by the interventions; 2) re-
duced responsiveness of arterial baroreceptors; 3) reduced
responsiveness of low pressure mechanoreceptors; 4) near
maximal stimulation of the sympathetic nervous system at
rest; or 5) failure of the heart to respond to increased sym-
pathetic stimulation.
The failure of plasma norepinephrine to increase con-
sistently during either nitroprusside infusion or orthostasis
in patients with heart failure suggests that the sympathetic
nervous system was not normally activated during these
stresses. However, the evidence for a striking elevation in
plasma norepinephrine levels during even modest exercise
HR CI 2 SVR
b/min Llmin/M dynes/sec/em -5
100 2.4 2500
l-t- -! I '",'" t
2------~ 2.0 1~· 2000 ~yl15 '1- 1Figure 3. Hemodynamic response to 60° head-up 1.6 1500
tilt in Group I (open squares) and in Group II (filled
l' r
squares) patients with congestive heart failure. Mean 50 i i i I
values ± standard error of the mean are shown in C T C T C T
control state (C) and after 10' of tilt (T). mrap = MAP mrap mewp
mean right atrial pressure; SVR = systemic vas- mmHg mmHg ~ mmHgcular resistance; other abbreviations and symbols 10 •are the same as in Figure 2. 100 30~1 8 "" ~It90 6 ""~. 20 "4 '~-80 2 !t
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Figure 4. Wilcoxon life table analysis of 21 patients in Group I
and 25 in Group II. Group I and Group II denote patients with
and without a rise in plasma norepinephrine, respectively, during
nitroprusside infusion.
in patients with heart failure (16,20,21) indicates that sym-
pathetic nervous system activity is not maximal at rest.
Abnormalities of arterial baroreflex control of heart rate
have been demonstrated in patients with heart disease (l,2,22)
and in animals with experimentally produced heart failure
(23-26). In heart failure augmentation of sodium and water
content of the arterial wall could decrease arterial compli-
ance (27) and be responsible for the diminished sensitivity
of baroreceptor reflexes. A decrease in sensitivity of atrial
receptors, as described by Greenberg (28) and Zucker (29)
and their co-workers in dogs with chronic heart failure,
appears to be related to changes in atrial compliance and
the morphologic characteristic of the receptor endings. Such
changes could also contribute to the impaired cardiac re-
sponse to vasodilators or orthostasis.
Abnormal neurohumoral responsiveness incongestive
heart failure. In the present series of patients with heart
failure one subset exhibited an essentially normal increase
in plasma norepinephrine levels in response to both nitro-
prusside infusion and orthostasis, whereas in the other subset
plasma norepinephrine levels declined. As might be ex-
pected, heart rate did not change in the latter group, but
even in the former group with evidence for a normal sym-
pathetic response to nitroprusside the mean increase in heart
rate was small and not statistically significant. It is not
known whether this paradox implies an altered parasym-
pathetic control of heart rate (22) or an impaired cardiac
response to sympathetic stimulation.
The subset of patients who exhibited no increase in plasma
norepinephrine in response to either nitroprusside infusion
or orthostasis clearly presented evidence for abnormal neu-
rohumoral responsiveness. Although this group had slightly
more severe left ventricular dysfunction and somewhat higher
plasma norepinephrine levels at rest, considerable overlap
between the groups made it impossible to identify this subset
on the basis of resting hemodynamic or hormonal mea-
surements. Because the hemodynamic effects of nitroprus-
side and head-up tilt were nearly identical in this group and
the more normally responding patients with heart failure, it
is difficult to ascribe the attenuated response to a lessened
baroreceptor or mechanoreceptor stimulus. Even when anal-
ysis was confined to those patients whose pulmonary wedge
pressure remained above 15 mm Hg during nitroprusside
infusion, the patients in Group I exhibited an elevation in
norepinephrine and the patients in Group 11 did not. The
most likely explanation is that the Group 11 patients had
striking abnormalities of both baroreceptor and mechano-
receptor function so that they failed to respond to a decrease
in arterial or atrial pressure either with a reflex release of
catecholamines.
The possibility that the higher baseline level of plasma
norepinephrine accounted for the unresponsiveness of the
patients in Group II cannot be excluded. However, plasma
norepinephrine increases promptly in response to exercise
in patients with heart failure (21). Patients with pheochromo-
cytoma and markedly elevated levels of circulating nor-
epinephrine exhibit a normal reflex elevation in response to
head-up tilt (30). Thus, it is unlikely that the heightened
sympathetic activity alone would inhibit a further reflex
increase in plasma norepinephrine levels unless the baro-
receptors and mechanoreceptors were directly involved in
the high levels at rest. Indeed, it is possible that abnor-
malities of these stretch receptors contribute to the elevated
plasma norepinephrine levels at rest by their failure to sup-
press sympathetic drive. In this case, the elevated levels
and nonresponse to nitroprusside and head-up tilt would be
manifestations of the same abnormality.
Despite the different neurohumoral response to nitro-
prusside infusion and head-up tilt in the two subsets, the
hemodynamic response to the interventions was similar in
both groups. Therefore, it appears that the acute response
of the sympathetic nervous system to these interventions
may not be an important determinant of the hemodynamic
effects.
Prognostic significance. The higher mortality observed
in the patients with abnormal reflex responsiveness suggests
that abnormalities of mechanoreceptor or baroreceptor func-
tion, or both, may serve as a sensitive indicator of severity
of heart failure. Whether this abnormality in neural control
is merely a sign of heart failure severity or actually con-
tributes to mortality cannot be ascertained. Reversal of heart
failure in dogs has been reported to reverse the decrease in
sensitivity of atrial stretch receptors (31). Further studies
are necessary to determine whether in patients the treatment
of congestive heart failure could correct this abnormal neu-
rohumoral response and in this way change the prognosis.
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